Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
August 09, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update

Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO...
August 05, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
July 29, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901

— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
July 01, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes

CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
June 20, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
June 17, 2019 06:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®

Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of...
June 16, 2019 12:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®

CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
June 13, 2019 17:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Results of Annual General Meeting

CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious...
June 04, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019

Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...

Next Page keyboard_arrow_right